- Supports accelerated growth of R&D, manufacturing, and commercial activities with new 100,000 sq-ft state-of-the-art facility
- Reinforces commitment to the region as Abcam approaches 20 years of US presence
Cambridge, UK, 13 July 2021: Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences reagents and tools, today announces the opening of a major new site in Waltham, MA.
The new facility is a central component of Abcam’s growth in the United States, reinforcing its commitment to support the research and biopharma sector globally and serving as a hub for the Company’s R&D and commercial activities in the region.
“Abcam’s first step toward global expansion was in 2003 at Kendall Square. Since then, the US has become our largest market. Investing in and expanding our presence in the vibrant Greater Boston cluster is another step in our journey to support biopharma partners and life sciences researchers globally, in their quest to accelerate discovery and the translation of these discoveries into improved human health outcomes.”
Alan Hirzel
CEO at Abcam
“Abcam’s first step toward global expansion was in 2003 at Kendall Square. Since then, the US has become our largest market. Investing in and expanding our presence in the vibrant Greater Boston cluster is another step in our journey to support biopharma partners and life sciences researchers globally, in their quest to accelerate discovery and the translation of these discoveries into improved human health outcomes.”
Alan Hirzel
CEO at Abcam
The 100,000 sq-ft site will increase the Company’s flexibility, scale, and capacity in R&D, Production, Distribution, and Customer Service required to address the increasing needs of the life sciences sector. The ability to provide critical reagents to support research in all areas of the life sciences is vital to enable scientific breakthroughs that underpin the rapid development of diagnostics, vaccines, and potential therapeutics.
“Massachusetts continues to attract life sciences companies from across the globe, who come here to access our leading academic and medical institutions, diverse talent, a supportive government, and a robust start-up community. We are thrilled to see Abcam outgrow its presence in Kendall Square and expand to Waltham, an area of growing interest for life sciences companies and one that is positioned for explosive growth in the coming years.”
Kendalle Burlin O’Connell
President and COO at MassBio
“Massachusetts continues to attract life sciences companies from across the globe, who come here to access our leading academic and medical institutions, diverse talent, a supportive government, and a robust start-up community. We are thrilled to see Abcam outgrow its presence in Kendall Square and expand to Waltham, an area of growing interest for life sciences companies and one that is positioned for explosive growth in the coming years.”
Kendalle Burlin O’Connell
President and COO at MassBio
This facility more than doubles Abcam’s capacity from its previous site in Kendall Square, Cambridge, MA and is expected to eventually house approximately 300 employees. The opening follows Abcam’s listing on NASDAQ in October 2020 and the establishment of its new cell engineering facility in the Bay area in December 2020.
Photography credits:
-
Duncan Lake of Cresa
-
Hannah Sistrand of JDL Corporate Interiors, Inc
Registered Office:
Discovery Drive, Cambridge
Biomedical Campus,
Cambridge, CB2 0AX, UK
+44 (0) 1223 696 000
VIEW PRODUCTS
© Abcam Limited. all rights reserved.
Abcam Limited is incorporated in England and Wales, its main country of operation in the UK. Use of this website is subject to our Terms and Conditions of use and our Privacy Policy. Share price and news information on this site is updated dynamically from external data feeds.
